Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure

Neoplasia

Volumn 8, Issue 5, 2006, Pages 364-372

  Olsen, Minna W B ^a   Ley, Carsten D ^a   Junker, Nanna ^a   Hansen, Anker J ^b   Lund, Eva L ^a   Kristjansen, Paul E G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Ang 4; Antiangiogenic; IFP; Migration; SCLC

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 4; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; MATRIGEL; RECOMBINANT ANGIOPOIETIN 4; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE PRESSURE; TUMOR CELL; TUMOR GROWTH;

EID: 33744802895     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06127     Document Type: Article

References (36)

1. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, and Yancopoulos GD (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180.
2. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, and Yancopoulos GD (2000). Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6, 460-463.
3. Kanda S, Miyata Y, Mochizuki Y, Matsuyama T, and Kanetake H (2005). Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res 65, 6820-6827.
4. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60.
5. Yu Q and Stamenkovic I (2001). Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 158, 563-570.
6. Tait CR and Jones PF (2004). Angiopoietins in tumours: the angiogenic switch. J Pathol 204, 1-10.
7. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, and Plate KH (2004). Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 165, 1557-1570.
8. Ley CD, Olsen MW, Lund EL, and Kristjansen PE (2004). Angiogenic synergy of bFGF and VEGF is antagonized by Angiopoietin-2 in a modified in vivo Matrigel assay. Microvasc Res 68, 161-168.
9. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, et al. (2004). Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516.
10. Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D, and Sekine I (2005). Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol 11, 964-969.
11. Nakayama T, Yoshizaki A, Kawahara N, Ohtsuru A, Wen CY, Fukuda E, Nakashima M, and Sekine I (2004). Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology 44, 232-239.
12. Lee HJ, Cho CH, Hwang SJ, Choi HH, Kim KT, Ahn SY, Kim JH, Oh JL, Lee GM, and Koh GY (2004). Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J 18, 1200-1208.
13. Xu Y, Liu YJ, and Yu Q (2004). Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. Cancer Res 64, 6119-6126.
14. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, et al. (1999). Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96, 1904-1909.
15. Heldin CH, Rubin K, Pietras K, and Ostman A (2004). High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4, 806-813.
16. Boucher Y, Lee I, and Jain RK (1995). Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res 50, 175-182.
17. Boucher Y, Leunig M, and Jain RK (1996). Tumor angiogenesis and interstitial hypertension. Cancer Res 56, 4264-4266.
18. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
19. Solly K, Wang X, Xu X, Strulovici B, and Zheng W (2004). Application of Real-Time Cell Electronic Sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2, 363-372.
20. Kragh M, Hjarnaa PJ, Bramm E, Kristjansen PE, Rygaard J, and Binderup L (2003). In vivo chamber angiogenesis assay: an optimized Matrigel plug assay for fast assessment of antiangiogenic activity. Int J Oncol 22, 305-311.
21. Rygaard K and Spang-Thomsen M(1997). Quantitation and Gompertzian analysis of tumor growth. Breast Cancer Res Treat 46, 303-312.
22. Kim KJ, Li B, Houck K, Winer J, and Ferrara N (1992). The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53-64.
23. Wang Y, Fei D, Vanderlaan M, and Song A (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7, 335-345.
24. Fadnes HO, Reed RK, and Aukland K (1977). Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 14, 27-36.
25. Boucher Y and Jain RK (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52, 5110-5114.
26. Lund EL, Thorsen C, Pedersen MW, Junker N, and Kristjansen PE (2000). Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Clin Cancer Res 6, 4287-4291.
27. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, and Isner JM (1998). Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83, 233-240.
28. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ, and Jiang C (2003). Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93, 664-673.
29. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, and Ferrara N (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57, 4593-4599.
30. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
31. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, and Kreutzer DL (1999). Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54, 567-572.
32. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, and Brambilla E (1999). Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEG-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188, 369-377.
33. Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O'dwyer ST, and Jayson GC (2006). Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapies. Eur J Cancer 42, 112-117.
34. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. (2000). Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60, 5565-5570.
35. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147.
36. Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A, Sunday ME, and Haley KJ (2002). Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 283, L585-L595.